Published in PLoS Pathog on June 13, 2013
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy | NCT02505009
Medical virology of hepatitis B: how it began and where we are now. Virol J (2013) 1.34
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (2015) 1.19
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog (2014) 1.16
Present and future therapies of hepatitis B: From discovery to cure. Hepatology (2015) 0.96
Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med (2015) 0.93
Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol (2015) 0.93
Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog (2013) 0.88
Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol (2014) 0.88
Therapeutic vaccination in chronic hepatitis B--approaches, problems, and new perspectives. Preface. Med Microbiol Immunol (2015) 0.87
Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol (2014) 0.87
Mouse models for therapeutic vaccination against hepatitis B virus. Med Microbiol Immunol (2014) 0.83
Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J Virol (2013) 0.83
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One (2014) 0.82
Hepatitis B: future curative strategies. Curr Opin Infect Dis (2014) 0.81
Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol (2014) 0.81
Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. Med Microbiol Immunol (2014) 0.80
Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Res (2015) 0.80
Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination. Mol Ther (2014) 0.79
Novel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins. J Virol (2013) 0.78
Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection. J Virol (2015) 0.78
A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection. Parasit Vectors (2015) 0.77
TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall. Mol Ther (2017) 0.76
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck. Med Microbiol Immunol (2014) 0.76
Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection. Int J Mol Sci (2015) 0.75
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
Drugs in Development for Hepatitis B. Drugs (2017) 0.75
Treatment of hepatitis B virus: an update. Future Microbiol (2016) 0.75
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature (1987) 2.85
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol (2003) 2.50
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J Immunol (1979) 2.15
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (2001) 1.99
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96
Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A (2009) 1.76
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol (1991) 1.76
Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology (1997) 1.58
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis (2001) 1.46
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med (1984) 1.41
Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology (2004) 1.28
Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog (2009) 1.26
Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology (2003) 1.24
Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking. J Virol (2007) 1.16
Specific vaccine therapy in chronic hepatitis B infection. Lancet (1994) 1.15
Evidence for long-range oncogene activation by hepadnavirus insertion. EMBO J (1994) 1.13
Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol (1999) 1.11
T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol (1998) 1.10
Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol (2001) 1.09
Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis (1999) 1.01
Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection (2003) 0.98
Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology (2002) 0.97
In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol (2005) 0.96
Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience. J Gastroenterol Hepatol (2012) 0.95
Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol (2007) 0.95
DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol (2012) 0.94
Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol (2012) 0.91
The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int (2013) 0.90
Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J Virol (1998) 0.89
Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat (2007) 0.88
Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol (2007) 0.88
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol (2002) 0.88
DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol (2000) 0.86
Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol (2003) 0.86
Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol (2003) 0.85
T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol (2001) 0.84
Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol (2003) 0.83
Quantitative assay of hepatitis B surface antigen in serum or plasma using laurell electrophoresis. Methods Mol Med (2004) 0.82
Lack of WHV integration nearby N-myc2 and in the downstream b3n and win loci in a considerable fraction of liver tumors with activated N-myc2 from naturally infected wild woodchucks. Virology (2005) 0.80
Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol (2009) 0.79
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
The complete genome sequence of the Arabidopsis and tomato pathogen Pseudomonas syringae pv. tomato DC3000. Proc Natl Acad Sci U S A (2003) 5.62
Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis (2013) 4.87
Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature (2012) 3.74
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
The TIGR rice genome annotation resource: annotating the rice genome and creating resources for plant biologists. Nucleic Acids Res (2003) 3.12
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Cutaneous dirt-adherent disease with single apparent transverse leukonychia on the fingernails. Arch Dermatol (2009) 2.65
Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat Mater (2012) 2.57
Gene RB cloned from Solanum bulbocastanum confers broad spectrum resistance to potato late blight. Proc Natl Acad Sci U S A (2003) 2.43
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler Thromb Vasc Biol (2010) 2.23
Disruption of tumor neovasculature by microbubble enhanced ultrasound: a potential new physical therapy of anti-angiogenesis. Ultrasound Med Biol (2011) 2.18
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol (2013) 2.10
The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China. Clin Ther (2007) 2.08
Visual word processing and experiential origins of functional selectivity in human extrastriate cortex. Proc Natl Acad Sci U S A (2007) 2.06
Hepatitis B virus rtI233V mutation and resistance to adefovir. N Engl J Med (2014) 1.99
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Molecular and cytological analyses of large tracks of centromeric DNA reveal the structure and evolutionary dynamics of maize centromeres. Genetics (2003) 1.92
Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res (2003) 1.88
Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol (2006) 1.82
DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol (2010) 1.82
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut (2010) 1.77
Draft genome of the kiwifruit Actinidia chinensis. Nat Commun (2013) 1.72
Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine (2003) 1.72
Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis (2007) 1.69
Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol (2012) 1.62
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 1.61
Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology (2005) 1.61
Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology (2007) 1.59
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
Awareness of rabies risks and knowledge about preventive measures among experienced German travel health advisors. J Travel Med (2006) 1.59
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57
Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol (2006) 1.56
Heritability of the specific cognitive ability of face perception. Curr Biol (2010) 1.52
Diversity in conserved genes in tomato. BMC Genomics (2007) 1.52
Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer (2010) 1.51
Risk of hepatitis C virus transmission from an infected gynecologist to patients: results of a 7-year retrospective investigation. Arch Intern Med (2002) 1.51
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50
Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol (2008) 1.49
Sequence, annotation, and analysis of synteny between rice chromosome 3 and diverged grass species. Genome Res (2005) 1.48
Amyloid beta₁₋₄₂ (Aβ₄₂) up-regulates the expression of sortilin via the p75(NTR)/RhoA signaling pathway. J Neurochem (2013) 1.46
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology (2010) 1.46
A pilot study of intense pulsed light in the treatment of Riehl's melanosis. Dermatol Surg (2010) 1.42
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer (2013) 1.40
Improved partition efficiency with threaded cylindrical column in vortex counter-current chromatography. J Chromatogr A (2011) 1.37
Characterization of virus isolates by particle-associated nucleic acid PCR. J Clin Microbiol (2005) 1.37
MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett (2011) 1.34
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol (2006) 1.32
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res (2004) 1.31
Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol (2012) 1.30
Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab (2009) 1.30
Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology (2011) 1.30
Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol (2008) 1.28
Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep (2013) 1.28
Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci (2010) 1.27
Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26
CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26
Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog (2009) 1.26
Comparative analyses of six solanaceous transcriptomes reveal a high degree of sequence conservation and species-specific transcripts. BMC Genomics (2005) 1.25
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
Resting-state neural activity across face-selective cortical regions is behaviorally relevant. J Neurosci (2011) 1.24
Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology (2008) 1.24
Gene expression profiling of potato responses to cold, heat, and salt stress. Funct Integr Genomics (2005) 1.23
NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of β-cells via JNK, p38 MAPK and p53 pathways. PLoS One (2010) 1.23
Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23
Immune control and prevention of chronic Friend retrovirus infection. Front Biosci (2007) 1.23
Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci U S A (2007) 1.22
Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther (2010) 1.21
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology (2009) 1.21
Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20
Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis (2005) 1.20
Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci U S A (2013) 1.19
Combining geometric morphometrics and functional simulation: an emerging toolkit for virtual functional analyses. J Anat (2010) 1.18